The Indian government is preparing to introduce a Minimum Import Price (MIP) on essential pharmaceutical raw materials. This decision comes as global supply chains face disruptions and the domestic pharmaceutical industry struggles with competition from cheaper imports, particularly from China.
The MIP will serve as a protective measure for local manufacturers, aiming to prevent a surge of low-priced Chinese goods that have been impacting domestic producers. By implementing this policy, the government hopes to stabilize the market and ensure a steady supply of critical raw materials.
Sources indicate that approximately ten key raw materials will be covered under this plan. These include active pharmaceutical ingredients and drug intermediates used for common medications like antibiotics and cholesterol treatments. This initiative is part of a broader strategy linked to the government’s Product-Linked Incentive (PLI) scheme, which aims to enhance local production capabilities and reduce dependency on foreign imports.
Industry experts have raised concerns regarding this proposed MIP, highlighting that higher costs for raw materials might eventually lead to increased production expenses for finished pharmaceuticals. A leading player in the sector expressed worries that the price hikes could create additional financial burdens on manufacturers.
Discussions between the pharmaceutical industry and the government have been ongoing, and a final decision is expected soon. Last year, the government had previously imposed an MIP on soda ash, marking one of its initial steps towards implementing this kind of trade protection.
As this situation evolves, stakeholders are keenly awaiting the government’s final decision on the MIP, which could significantly impact India’s pharmaceutical landscape.
-Rashmi Kumari
